Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Licensing deals
Biotech
Ionis bags $30M from Recordati for ex-US rare disease rights
Ionis has offloaded regional rights to a near-approval rare disease asset, pocketing $30 million upfront from Recordati for an ex-U.S. license.
Nick Paul Taylor
Jun 25, 2026 6:59am
Serapha takes flight with $230M, gene-editing prospect from China
Jun 23, 2026 1:55pm
Biogen is remaking its pipeline with an ‘entrepreneurial spirit’
Jun 16, 2026 8:50am
Novartis sticks 2nd deal with Orionis, this one worth up to $1.4B
Jun 10, 2026 8:21am
Lilly licenses AlzeCure Alzheimer’s asset for $1B biobucks
Jun 9, 2026 10:16am
GSK pledges £44M to UK biotech to explore fibrosis regression
Jun 8, 2026 8:50am
